Scholarlink

Background <p>Myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction, causing muscle weakness. Respiratory failure can develop quickly, increasing mortality. Despite treatment advances, MG-related respiratory mortality in the U.S. remains poorly understood.</p> Objective <p>To analyze mortality trends due to myasthenia gravis and respiratory failure in the United States from 1999 to 2020, stratified by sex, region, and urban–rural status, using data from the CDC Wonder database.</p> Method <p>We conducted a retrospective analysis using death certificates from the CDC Wonder share database (1999–2020) with ICD-10 codes G70, J96.0, J96.1, and J96.9. Age-adjusted mortality rates per 100,000 population were determined. The annual percent change (APC) and its related 95% CI in AAMR were analyzed using the Joint-point Regression Program to identify temporal trends.</p> Results <p>A total of 9937 deaths from MG and RF in US adults aged ≥ 25 were identified during the study period—males exhibited higher mortality than females (AAMR: 0.265 vs 0.148). AAMR increased significantly (AAPC:3.91%; 95% CI:2.77–5.07), with a marked rise after 2010. Most deaths occurred in inpatient settings (71%). Regional disparities were also noted, with Southern US and metropolitan areas showing the highest AAMRs. During the COVID-19 pandemic, a significant spike in mortality was reported from 2019 to 2020.</p> Conclusion <p>MG-attributable respiratory mortality has increased over the past two decades with significant demographic and geographic variations. Thus, there is an acute need for targeted and equitable healthcare strategies to highlight ongoing disparities in access.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Temporal Trends in Mortality from Myasthenia Gravis and Respiratory Failure in the United States (1999–2020): Insights from CDC WONDER

  • 期刊论文

  • 发表日期：

    2025年10月2日

查看全文
  • Tehreem Asghar,
  • Syed Muhammad Ali Akbar,
  • Syed Muhammad Salman Hassan,
  • Ayesha Khan,
  • Maryam Asghar,
  • Haseeba Khalid,
  • Zahra Nawaz,
  • Hammad Mudassar,
  • Zuhaab Khan,
  • Humayun Anjum

摘要

Background

Myasthenia gravis is a chronic autoimmune disorder affecting the neuromuscular junction, causing muscle weakness. Respiratory failure can develop quickly, increasing mortality. Despite treatment advances, MG-related respiratory mortality in the U.S. remains poorly understood.

Objective

To analyze mortality trends due to myasthenia gravis and respiratory failure in the United States from 1999 to 2020, stratified by sex, region, and urban–rural status, using data from the CDC Wonder database.

Method

We conducted a retrospective analysis using death certificates from the CDC Wonder share database (1999–2020) with ICD-10 codes G70, J96.0, J96.1, and J96.9. Age-adjusted mortality rates per 100,000 population were determined. The annual percent change (APC) and its related 95% CI in AAMR were analyzed using the Joint-point Regression Program to identify temporal trends.

Results

A total of 9937 deaths from MG and RF in US adults aged ≥ 25 were identified during the study period—males exhibited higher mortality than females (AAMR: 0.265 vs 0.148). AAMR increased significantly (AAPC:3.91%; 95% CI:2.77–5.07), with a marked rise after 2010. Most deaths occurred in inpatient settings (71%). Regional disparities were also noted, with Southern US and metropolitan areas showing the highest AAMRs. During the COVID-19 pandemic, a significant spike in mortality was reported from 2019 to 2020.

Conclusion

MG-attributable respiratory mortality has increased over the past two decades with significant demographic and geographic variations. Thus, there is an acute need for targeted and equitable healthcare strategies to highlight ongoing disparities in access.

Graphical Abstract